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508Objective: The present study sought to determine whether the Hedgehog (Hh) pathway is active and regulates
the cell growth of cultured malignant pleural mesothelioma (MPM) cells and to evaluate the efficacy of pathway
blockade using smoothened (SMO) antagonists (SMO inhibitor GDC-0449 or the antifungal drug itraconazole
[ITRA]) or Gli inhibitors (GANT61 or the antileukemia drug arsenic trioxide [ATO]) in suppressing MPM
viability.
Methods: Selective knockdown of SMO to inhibit Hh signaling was achieved by small interfering RNA in 3
representativeMPM cells. The growth inhibitory effect of GDC-0449, ITRA, GANT61, and ATOwas evaluated
in 8 MPM lines, with cell viability quantified using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Cell death was determined by annexinV/propidium iodide staining and flow cytometry.
Results: SMO small interfering RNA mediated a two- to more than fivefold reduction of SMO and Gli1 gene
expression as determined by real-time quantitative reverse-transcriptase polymerase chain reaction, indicating
significant Hh pathway blockade. This was associated with significantly reduced cell viability (34%  7% to
61% 14% of nontarget small interfering RNA controls; P¼ .0024 to P¼ .043). Treating MPM cells with Hh
inhibitors resulted in a 1.5- to 4-fold reduction of Gli1 expression. These 4 Hh antagonists strongly suppressed
MPM cell viability. More importantly, ITRA, ATO, GANT61 induced significant apoptosis in the representative
MPM cells.
Conclusions: Hh signaling is active in MPM and regulates cell viability. ATO and ITRAwere as effective as the
prototypic SMO inhibitor GDC-0449 and the Gli inhibitor GANT61 in suppressing Hh signaling in MPM cells.
Pharmaceutical agents Food and Drug Administration–approved for other indications but recently found to
have anti-Hh activity, such as ATO or ITRA, could be repurposed to treat MPM. (J Thorac Cardiovasc Surg
2014;147:508-16)Malignant pleural mesothelioma (MPM) is an uncommon,
yet deadly, cancer that is etiologically linked to asbestos
exposure. No effective standard therapy is available for
this disease. Surgically resectable MPM should be treated
with a combination of surgery, chemotherapy, and radio-
therapy, a treatment strategy with significant morbidity
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The Journal of Thoracic and Cardiovascular Surg(stage III) to 30 months (stage I).1 Inoperable MPM should
be treated with palliative chemotherapy, which results in a
median survival of approximately 9 months.2 From the
experimental therapeutic perspective, considerable effort
has been placed on testing novel anticancer drugs such as
histone deacetylase inhibitors, new combinations of known
chemotherapy agents, and targeting the usual receptor
tyrosine kinases such as epidermal growth factor receptor
(EGFR). All without significant improvement in survival,
however.3 A new treatment paradigm is urgently needed.
The embryonic/developmental signal transduction
pathway mediated by the Hedgehog (Hh) ligands plays a
crucial role during embryogenesis by regulating body
patterning, cellular proliferation, and differentiation.4 It is
largely silenced in terminally differentiated cells until
reactivated by tissue injury to mediate cellular regeneration
and repair.4 Activation of the Hh pathway has recently
been shown to play a causative or facilitating role in the
development and/or maintenance of cancer.4 The molecular
mechanisms of asbestos-induced carcinogenesis include
chronic inflammation and tissue injury and repair, genera-
tion of oxygen free radicals, DNA damage, activation of
mitogenic signal transduction pathways, and transcription
factors.5 Significant crosstalk occurs among these activatedery c January 2014
Abbreviations and Acronyms
ATO ¼ arsenic trioxide
GDC ¼ GDC-0449
EGFR ¼ epidermal growth factor receptor
FDA ¼ Food and Drug Administration
Hh ¼ hedgehog
HPI ¼ Hedgehog pathway inhibitor
IC50 ¼ drug concentration that mediates 50%
inhibition of cell number or viability
ITRA ¼ itraconazole
MPM ¼ malignant pleural mesothelioma
mRNA ¼ messenger RNA
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide
PCR ¼ polymerase chain reaction
PI ¼ propidium iodide
PTCH ¼ patched
RT ¼ reverse transcriptase/reverse transcribed
siNT ¼ nontarget scramble control siRNA
siRNA ¼ small interfering RNA
siSMO ¼ siRNA targeting SMO
SMO ¼ smoothened
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reactivated in MPM or even contributes to its tumorigenesis
is not completely known.
The canonical signal transduction mediated by members
of the secreted Hh proteins (sonic Hh, Indian Hh, and desert
Hh) starts with binding of the ligands to their receptor
Patched (PTCH), which then relieves its inhibitory activity
on the signal transducer smoothened (SMO).4 Uninhibited
SMO translocates to, and accumulates in, the primary
cilium, where it processes and transmits Hh signals to the
nucleus by way of the transcription activators Gli2/3,
leading to increased expression of many proteins, including
the transcription factor Gli1, that are essential for tumor
development.4 Thus,Gli1mRNA levels are physiologically
relevant indicators of Hh signaling pathway activity4
(Figure 1). Additional advances in Hh signaling research
has demonstrated that Hh proteins can also signal through
Gli-independent mechanisms, commonly referred to as
‘‘noncanonical’’ Hh signaling cascades (type I, Hh/PTCH/
SMO-independent/Gli-independent signaling; or type II,
Hh/PTCH/SMO-dependent/Gli-independent signaling).4
Moreover, elevated Gli1 expression levels have been
observed in many tumors independent of Hh.6 The most
practical strategy to inhibit Hh activity for therapeutic
purposes is to block the function of either SMO or Gli1/2
with pharmacologic antagonists (Hh pathway inhibitors
[HPIs]). Many SMO inhibitors are in various stages of
clinical development, with 1 (GDC-0449 [GDC] or vismo-
degib) approved by the US Food and Drug AdministrationThe Journal of Thoracic and Ca(FDA) for the treatment of metastatic skin basal cell carci-
noma.7,8 Itraconazole (ITRA), a commonly used drug to
treat invasive mycosis, has recently been identified by
drug screening to be a potent SMO inhibitor.9 Similarly,
many Gli antagonists, such as GANT61, are also in
preclinical development.10-12 Arsenic trioxide (ATO),
FDA-approved for the treatment of acute promyelocytic
leukemia, has been shown to inhibit Gli transcriptional
activity and to be active against Gli-driven tumors in vitro
and preclinical in vivo models.13,14
The primary objective of our present study was to
determine whether the Hh pathway is active in MPM cells
and contributes to cell proliferation. We planned to
repurpose and develop ITRA and ATO as HPIs to treat
Hh-dependent cancers. Therefore, the second objective of
the present study was to comparatively evaluate the
therapeutic efficacy of HPIs in cultured MPM cells using
SMO antagonists (either ITRA or SMO GDC-0449,
specifically designed by the medicinal chemistry inhibitor
of SMO) or Gli antagonists (either ATO or GANT61, the
selective Gli inhibitor identified by drug screen).
METHODS
Cell Lines and Reagents
Cultured MPM cells (generously provided by Dr D. S. Schrump,
National Cancer Institute, National Institutes of Health, Bethesda, Md;
and Dr H. I. Pass, New York University, New York, NY) were maintained
in Roswell Park Memorial Institute-1640 supplemented with 5% fetal calf
serum and glutamine (10 mM) and penicillin/streptomycin). The MPM
cells used in the present study were H513, Gates, Gardner (epitheliod
subtype), H2373, H2052, REN (sarcomatoid subtype), H2452 (biphasic),
and H290 (unknown). ITRA and ATO were purchased from Sigma-
Aldrich (St Louis, Mo). GANT61 was purchased from Tocris Bioscience
(Minneapolis, Minn), and GDC-0449 (GDC) was obtained from Selleck
Chemicals (Houston, Tex). ITRA was dissolved in 0.2 N HCl in ethanol.
ATO was dissolved in 0.04 N NaOH in Dulbecco’s phosphate-buffered
saline. GANT61 and GDC were dissolved in dimethyl sulfoxide. All
described experiments were performed in Roswell Park Memorial
Institute-1640 with 2% fetal calf serum.
Quantitative Reverse-Transcriptase Polymerase
Chain Reaction
Cells seeded in 6-well plates were collected in 0.5 mL of Trizol reagent
(Invitrogen, Grand Island, NY) at the indicated times after treatment with
HPIs or small interfering RNA (siRNA). Total RNA was isolated and
reverse transcribed (RT) using the Complementary DNA Synthesis Kit
from Bio-Rad (Hercules, Calif). Real-time polymerase chain reaction
(PCR) was conducted using SYBR Green Supermix from Bio-Rad in a
MyiQ single-color thermocycler (Bio-Rad). Real-time RT-PCR primers
were purchased from Sigma-Genosys (The Woodlands, Tex). The Ct
data were generated using the software accompanying the thermocycler,
and the messenger RNA (mRNA) levels were calculated using the OCt
method, with glyceraldehyde-3-phosphate dehydrogenase as the internal
control (Ct Gli  Ct GAPDH) and presented as arbitrary units as
2(OCt) 3 105.
siRNA Assays
Representative MPM cells were seeded in 6-well plates and, after an
overnight incubation, were transfected with 50 nM of either pooledrdiovascular Surgery c Volume 147, Number 1 509
FIGURE 1. Diagrammatic representation of the canonical Hedgehog (Hh)-mediated signal transduction pathway in eukaryotes. In the absence of
Hh ligands, the cognate Hh receptor patched (ptc) suppresses the activity of the signal transducer smoothened (Smo) by preventing SMO from translocating
to the primary cilium, a membrane-encased protrusion located on the apical side of polarized cells that was initially thought to be a vestigial organelle but has
now been proved to be essential for Hh-mediated signaling. In the absence of activated SMO in the primary cilium, Gli2/3 transcription factors are processed
to become repressors (Gli2/3R). Binding of Hh ligands to patched (PTCH) leads to ligand/receptor internalization and degradation, which allows SMO
translocation to the primary cilium where it mediates activation of Gli2/3 to form the transcriptional activators Gli2/3A. Gli2/3R move to the nucleus
and mediate Hh-dependent gene transcription. The Hh-mediated signal transduction pathway can be attenuated by targeting SMO using pharmacologic
inhibitors such as GDC-0449, itraconazole (ITRA) or others currently in development or by targeting the transcription activators Gli1/2 usingGli antagonists
such as GANT61, arsenic trioxide (ATO), or other selective Gli inhibitors. Interested readers are referred to the study by Robbins and colleagues4 for a full
description of the Hh signaling network.
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(siSMO; Dharmacon, Lafayette, Colo) using INTERFERin (Polyplus-
transfection, New York, NY) according to the transfection protocol of
the manufacturer. The cells were collected 72 hours after siRNA
transfection and subjected to real-time RT-PCR for SMO and Gli1
expression. For growth proliferation assays, the cells transfected with either
siNT or siSMO and were cultured for 96 hours. Cell viability was assayed
using the MTT and were expressed as percentages of siNT-treated cells.
Assay for AntiHh Activity of HPIs
The Hh pathway reporter sHh-Light2 cells (NIH-3T3 cells stably
transfected with the reporter cassette 8XGli1-luciferase that respond to
SMO stimulation) were activated with either conditioned media of iHH
cells15 containing the sHhN ligand or the SMO agonist SAG with or
without the presence of HPIs, which were added to the cells 2 hours before
SMO activation. Unactivated (negative controls) and activated (positive
controls) and activated sHHhLight2 cells treated with HPIs were assayed
for luciferase activity and expressed as the percentage of luciferase activity
of SMO-stimulated sHh-Light2 cells.
Cell Proliferation and Cell Death Assays
For the dose-dependent cell viability assay, MPM cells were seeded in
96-well plates at predetermined densities to avoid overconfluence of the
control cells at the end of the experiments. After an overnight incubation,
the cells were treated at the indicated concentrations of HPIs or drug
carriers in 200 mL for 96 hours with replacement of fresh media with drugs
or carriers 48 hours after the onset of drug treatment. The cell number or
viability was measured using the MTT assay and expressed as the510 The Journal of Thoracic and Cardiovascular Surgpercentage of untreated controls. For the cell proliferation assay, 20,000
cells were seeded in 24-well plates and treated with HPIs at the indicated
concentrations (with a change of media at 48 and 96 hours after the onset
of the experiments), and the cell number or viability was enumerated daily
for 5 days using the MTT assay and expressed as the x-fold increase of the
MTT optical density at wavelengths of 570 nm/650 nm. For the cell death
assay, MPM cells were seeded in 12-well plates at 40,000 cells and treated
with the indicated concentrations of HPIs for 60 hours and subjected to
annexinV/PI staining and flow cytometry for enumeration of cell death:
apoptosis (early, annexinVþ/PI; late, annexinVþ/PIþ) and necrotic
death (annexinV/PIþ). For cell cycle analysis, MPM cells were treated
with the indicated concentrations of HPIs for 48 hours, harvested by
trypsinization, fixed with paraformaldehyde, and stained with PI/RNAse.
The cell cycle distribution was determined using flow cytometry.
Data Presentation and Statistical Analysis
The experiments were performed at least in triplicate, and the data are
expressed as the mean  standard deviation. The 2-tail Student t test and
analysis of variance with Bonferroni’s post test for pairwise comparison
was used as indicated for the statistical analysis (GraphPad software, San
Diego, Calif).RESULTS
Hh Pathway Is Active and Controls Cell Growth in
MPM
Real-time quantitative RT-PCR analysis for the expres-
sion of key components of the Hh pathway (PTCH, SMO,ery c January 2014
FIGURE 2. The Hedgehog pathway is active and contributes to cell proliferation in representative culturedmalignant pleural mesothelioma cells. The cells
were transfected with pooled scramble nontarget small interfering RNA (siNT) or small interfering RNA targeting smoothened (siSMO) and assayed for
SMO messenger RNA (mRNA) (on-target effect) and Gli mRNA (Hedgehog pathway activity) and cell viability (n ¼ 3, mean  standard deviation,
#P ¼ .002, ##P ¼ .009, *P ¼ .04) and representative quantitative reverse-transcriptase polymerase chain reaction data of 3 independent experiments.
You et al Evolving Technology/Basic ScienceGli1/2, and the Hh ligands) indicated that all cultured MPM
cells had detectable mRNA levels of these genes (data not
shown). To determine whether the Hh pathway is active in
MPM cells, we selectively suppressed SMO gene expres-
sion using siRNA in representative MPM cells H2373,
Gardner, and H242 and assayed for Gli1 mRNA using
quantitative RT-PCR. Compared with the siNT, siSMO
significantly reduced not only the SMO transcripts, but
also Gli1 gene expression, indicative of attenuation of
pathway activity. More importantly, suppression of Hh
signaling was associated with a 40% to 60% reduction of
cell proliferation (Figure 2), implicating the role of the
Hh pathway in cell proliferation.E
T
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Using the prototypic SMO inhibitor GDC as the positive
control, we sought to determine the Hh pathway inhibitory
activity of the Gli inhibitor GANT61 and also of the two
repurposed Hh antagonists ITRA and ATO, first in the
reporter cells sHH-Light2 stimulated with either the Hh
ligand or the pharmacologic SMO agonist SAG and, subse-
quently, in representative MPM cells. Complete attenuation
of Hh signaling was observed in the activated sHH-Light2
cells treated with GDC at concentrations as low as 50 nM
or ITRA at concentrations of 2.5 mM. Both SMO
inhibitors were much more effective in blocking pathway
activation mediated by Hh ligand acting on PTCH upstream
of SMO than that mediated by SAG acting on SMO itself.
The two Gli inhibitors, GANT61 and ATO, exhibited aThe Journal of Thoracic and Casimilar profile of inhibiting pathway activation mediated
by either Hh ligand or SAG (Figure 3, A). More importantly,
treating representative MPM cells with these HPIs for 24
hours resulted in attenuation of Hh signaling, indicated by
a 1.5- to>5-fold reduction of Gli1 mRNA (Figure 3, B).Suppression of MPM Cell Growth by HPIs
We next evaluated the growth inhibitory effects of these
4 HPIs on a panel of 8 MPM cells by performing dose–
response cell viability and time-course cell proliferation
assays. Data from the representative experiments are shown
in Figure 4. Significant dose-dependent suppression of cell
number or viability was observed in the cells treated with
these HPIs, with ITRA exerting the strongest effect. In
contrast, the selective SMO inhibitor GDC demonstrated
only mild to moderate reduction of cell viability. The cell
proliferation assay showed that although GDC resulted in
a mild reduction of cell proliferation, ITRA, ATO, or
GANT61, not only suppressed cell growth, but also caused
a net loss of cell numbers, indicative of a strong induction of
cell death. The susceptibility of the 8 MPM cells to the
antiproliferation effects of these 4 HPIs was quantified by
estimating the drug concentration that mediated 50%
inhibition of cell number or viability (IC50) from respective
dose–response curves similar to those shown on Figure 4, A.
All MPM cells evaluated in our study were very sensitive to
ATO and ITRA with IC50s<5 mM. However, the IC50s of
GDC ranged from 15 to 20 mM in 5 of 8 and was not reached
in 3 of 8 other MPM cells (Figure 5, A). In the following setrdiovascular Surgery c Volume 147, Number 1 511
FIGURE 3. A, Attenuation of Hedgehog (HH) pathway activation by the selective smoothened inhibitor GDC-0449, the selective Gli inhibitor GANT61,
and the repurposed HH antagonists itraconazole and arsenic trioxide. Pathway activity was bioassayed using the sHh-Light2 cells stimulated with either sHh
ligand or the pharmacologic smoothened agonist SAG, with or without Hedgehog pathway inhibitors (HPIs). Luciferase activity of unstimulated (basal),
stimulated without (0) and with HPI treatment (at indicated drug concentrations) was measured and is expressed as the percentages of luciferase activity in
the stimulated reporter cells n¼ 4, mean standard deviation. B, Suppression of HH activity in representative malignant pleural mesothelioma cells by the
HPIs. The cells were treated with 1 of the 4 HPIs at indicated concentrations for 24 hours and assayed for Gli1 messenger RNA using quantitative reverse
transcriptase polymerase chain reaction. Representative data of 3 independent experiments with similar results shown. GDC, GDC-0449; ITRA, itracona-
zole; ATO, arsenic trioxide; mRNA, messenger RNA.
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mechanism of the HPI-mediated growth inhibitory effect.
Representative MPM cells were treated with 5 or 20 mM512 The Journal of Thoracic and Cardiovascular Surgof each of these HPIs for 60 hours and were subjected to
cell cycle analysis or assayed for cell death (early, late
apoptotic, and necrotic death). Exposure to GDC did notery c January 2014
FIGURE 4. A, Dose-dependent cytotoxicity of Hedgehog pathway inhibitors (HPIs) on 2 representative cultured malignant pleural mesothelioma cells
(n ¼ 4-6, mean  standard deviation). Cells seeded in 96-well plates were continuously exposed to HPIs at the indicated concentrations for 96 hours,
and the cell number/viability was quantified using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. B, Suppression of
cell proliferation by HPIs, in particular, with GANT61, itraconazole (ITRA), or arsenic trioxide (ATO), mediated a net reduction in cell viability, indicative
of a significant induction of cell death (representative data from 3 independent experiments). Cells seeded in 24-well plates were continuously treated with
HPI at the indicated concentrations for 5 days, and the cell number or viability was quantified daily using MTT under constant experimental conditions and
expressed as the x-fold changes from the baseline MTT optical density of the control cells on day 0 when HPI treatment started. GDC, GDC-0449.
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significant cell death was observed after ITRA, ATO, or
GANT61 treatment (Figure 5, B). In addition to causing
cell death, ATO, ITRA, and GANT61 also inhibited cell
progression through the cell cycle at G1/S and/or G2/M
checkpoints with accumulation of cells in G0/G1 or G2/M
subpopulations. Delayed progression through the S phase
was also observed in the H2373 cells treated with the Gli
inhibitors ATO and GANT61. Delayed transition at the
G/S checkpoint was observed in the GDC-treated cells,
with the accumulation of cells in G0/G1 and concomitant
reduction of cells in S and G2/M phases (Figure 5, C).
DISCUSSION
Molecularly targeted therapy, either alone or combined
with standard cytotoxic chemotherapeutic agents, is now a
well-established treatment strategy for hematologic and
solid cancer. Targeted therapy is most effective when
applied to tumors that are addicted to, or at least dependent
on, the molecular pathway or process being targeted. The
prime example is the efficacy of the EGFR-tyrosine kinase
erlotinib or gefitinib in treating advanced adenocarcinoma
harboring activating EGFR mutations.16 In addition to
many well-described membrane-associated receptor tyro-
sine kinase or the intracellular serine/threonine kinaseThe Journal of Thoracic and Casignal transduction pathways that can be oncogenic when
dysregulated, other signaling cascades, such as Notch,
Wnt, or Hh, well recognized as being crucial for embryonic
development and stem cell function, have recently been
implicated in cancer initiation and development.17,18
Hh-mediated signaling is the oncogenic driver for skin basal
cell carcinomas, with constitutively active Hh pathway due
to loss of PTCH expression.19,20 Consequently, selective
targeting of SMO with GDC-0449 results in significant
clinical responses in advanced skin basal cell carcinoma
refractory to standard therapy.7 Our laboratory and
others have demonstrated the role of Hh signaling on the
tumorigenesis of many malignant tumors, including
primary cancer of the lung, prostate, bladder, pancreas,
and brain.17,18,21-23 A number of novel Hh inhibitors,
identified by screening of the chemical library or
medicinal chemistry design for SMO or Gli inhibitory
activity, have now entered clinical trials,19,20 where they
will be extensively tested for many years for efficacy and
toxicity, with only a small percentage of them eventually
receiving FDA approval. Alternatively, screening of FDA-
approved pharmaceutical agents currently used to treat
various medical conditions has also identified certain agents
that can effectively inhibit Hh signaling, such as ITRA or
ATO.9,13,14 These 2 drugs have been used for years, andrdiovascular Surgery c Volume 147, Number 1 513
FIGURE 5. A, Comparative analysis of growth inhibitory effect of Hedgehog pathway inhibitors (HPIs) on the panel of 8 cultured malignant pleural
mesothelioma cells as demonstrated by the drug concentration that mediated 50% inhibition of cell number or viability. These values were estimated
from the respective dose–response curves shown in Figure 3, A. B, Induction of cell death by itraconazole (ITRA), arsenic trioxide (ATO), and
GANT61, but not GDC-0449 (GDC) on 3 representative malignant pleural mesothelioma cells (n¼ 4-6, mean standard deviation; #analysis of variance,
P¼ .027, withP<.05 for GDC 20 mMvs control only using Bonferroni’s post test analysis; ##analysis of variance,P¼ .026, withP<.05 for GDC 20 mMvs
control using Bonferroni’s post test analysis; *no significant difference between GDC-treated and control cells). C, Suppression of cell cycle progression by
HPIs. Cell cycle arrest at G1/S, S/G2, or G2/M checkpoints were observed in malignant pleural mesothelioma cells treated with HPIs with concomitant
accumulation of cells at the G0/G1 or S or G2/M compartments (percentages shown in bold) of the cell cycle. Representative data of 3 independent
experiments are shown.
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been well described. Repurposing of FDA-approved drugs
with known toxicity profiles for cancer therapy circum-
vents the lengthy process of phase I drug development.
Multiple clinical trials (NCT00769600, NCT00887458,
NCT00798135, and NCT01108094)24 have been conducted
to evaluate the efficacy of ITRA in treating non–small-cell
lung cancer (combined with pemetrexate),25 prostate can-
cer,26 and breast cancer.
Our data have demonstrated that Hh signaling is active in
cultured MPM cells and contributes to cell growth in vitro,
in keeping with only 1 previous report on the mitogenic role
of Hh signaling in primary MPM tumors.27 Although
mediating a reduction of Gli1 expression in MPM cells
(Figure 3, B) comparable to that of other HPIs, GDC had
the lowest antiproliferative activity (high IC50 values;
Figure 5, A). ITRA and ATO likely have other
Hh-independent (off-target) growth inhibitory effects. The
molecular mechanism of ATO-mediated anticancer activity
is diverse, including generation of reactive oxygen free
radicals, inhibition of mitogenic and survival signal
transduction pathways, and induction of apoptosis.28,29
ITRA has been shown to inhibit mammalian target of
rapamycin signaling and membrane growth factor
trafficking, causing death of endothelial cells24; however,
its effect on cancer cell growth and survival has not been
well elucidated. GANT61, being a Gli inhibitor, targets
both SMO-dependent and SMO-independent Gli transcrip-
tional activity and has been shown to exert profound
anticancer property in preclinical models of solid
tumors.11,12 The cell culture condition used in our study
could influence the magnitude of Hh activation and, thus,
the efficacy of the selective SMO inhibitor GDC.
Significant activation of Hh signaling and sensitization to
the growth inhibitory effect of pathway attenuation was
observed in bladder cancer cells with low intrinsic Hh
activity (which were thus resistant to the antiproliferative
effect of pathway blockade) when these cells were
cultured in anchorage-independent growth conditions,
instead of grown as a monolayer.21 Even if the Hh-
independent drug effect might be largely responsible for
the profound cytotoxicity of ITRA or ATO on MPM cells,
drug-induced reduction of Gli1 expression could still serve
as a pharmacodynamic biomarker.
The results of our study raise many questions and thus
provide guidance for the direction of our future works.
The frequency and magnitude of Hh pathway activation
needs to be determined inMPM tissues using immunohisto-
chemical staining for Gli1 expression in tissue microarrays.
A more comprehensive analysis of Hh pathway activation
and the growth inhibitory effect of pathway attenuation
(either by siSMO-mediated gene knockdown or by selective
SMO inhibitors) will be done in a larger panel of MPM cells
cultured using either anchorage-dependent or anchorage-The Journal of Thoracic and Caindependent conditions. Biomarkers predictive of the
cellular sensitivity to HPIs need to be developed and vali-
dated early in the course of drug development. Such
biomarkers will be used to properly select tumors most
likely to response to Hh-targeted therapy. The molecular
mechanism of ITRA-induced cytotoxicity will also be the
focus of our future investigation. Finally, we plan to
translate our in vitro findings to preclinical in vivo study
using animal models of human MPM xenografts.
In conclusion, our data have indicated that Hh signaling
is active and regulates cell proliferation of cultured MPM
lines. Repurposing pharmaceutical agents approved by the
FDA for other clinical indications but also shown to be
HPIs, such as ITRA or ATO, to treat Hh-dependent cancers
such as MPM might shorten the lengthy process of drug
development and allow rapid entrance into clinical
application.References
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Dr Jules Lin (Ann Arbor, Mich).DrNguyen, congratulations on
your work and an excellent presentation.
You have identified potential therapeutic targets for MPM in the
Hh pathway, SMO and Gli, and identifying a novel target is a good
first step. We are often frustrated by the lack of inhibitors, and this
approach you have taken is exciting, to find a commonly used drug
that has been extensively tested in humans that happens to inhibit
the targets you have identified to treat MPM.
I have 3 questions for you. ITRA has many different effects, and
it affects other pathways, including the mammalian target of rapa-
mycin pathway. Did you confirm that the effects that you see here
are from the inhibition of the Hh pathway? For example, did you
inhibit a downstream mediator, such as Gli, with a small hairpin
RNA to see whether that eliminates the effect of ITRA?
Dr Nguyen. That is a very good point. ITRA has been shown to
target the mammalian target of rapamycin in signaling of the
vascular endothelial growth factor receptors in endothelial cells.
I did a lot of searching. I could not really find good studies on
the effect of ITRA in cancer cells. It will be the next step for us
to determine what ITRA does in cancer cells. Your comment about516 The Journal of Thoracic and Cardiovascular Surgselectively targeting an Hh pathway component such as Gli to
determine the relative contribution of Hh inhibition in mediating
the growth inhibitory effect of itraconazole is valid. In this case,
I would knockdown SMO because it is the target of ITRA. I agree
with you that ITRA has other effects that inhibit cancer cell
growth. The antiproliferation effect we observed might not all be
coming from SMO inhibition. Also, even if the anticancer effect
is SMO independent, we can always use Gli knockdown as a
marker of the drug effect on the cells. That is a very good point.
Dr Lin.My second question is, in basal cell carcinoma, as you
mentioned, PTCH was decreased and that was the mechanism for
Hh overexpression in the basal cells. In MPM, what is the
exact alteration? In your cell lines, did you see certain genes that
were overexpressed and that correlated with the treatment
response? Which would be the best biomarker for the treatment
response?
Dr Nguyen. I appreciate those comments a lot. A recently
published study in the International Journal of Oncology
(2012;41:1751-61) examined the antiproliferation effect of
cyclopamine—a prototypic SMO inhibitor—in a large collection
of cancer cell lines of epithelial origin. The investigators screened
for activating mutations of PTCH or SMO, and they observed
none. It only seems to occur in basal cell carcinoma or medullo-
blastoma. However, the Hh pathway can be activated by other
mechanisms, including overexpression of the ligands. More
importantly, evidence has shown that the Hh pathway can be acti-
vated by a paracrine effect with ligands coming from the tumor
microenvironment (low Hh activity in in vitro cultures but high
levels of activation in tumor xenografts). We do not see that in
the in vitro system. The other report has shown that the method
we use to grow cells can affect Hh signaling. We grow cells as a
monolayer on plastic ware. So, my next step would be to study
cells grown as spheroids. Other investigators have shown that in
the spheroid-grown condition, pathways such as Notch, Wnt, or
Hh are activated. Thus, that would be another way of looking at
it. What you referred to in your last question is the identification
of a biomarker or gene signature predictive of the treatment
response. That is the next step of our research project. I appreciate
that insightful comment.
Dr Lin. Then, my final question, Dr Jablons’ group at the Uni-
versity of California, San Francisco, found that Gli2 was overex-
pressed, and they thought that resulted from a SMO-independent
pathway, perhaps transforming growth factor-b. Did you consider
that at all, and did you find any synergistic effects if you inhibited
both SMO and Gli at the same time?
Dr Nguyen. Can you repeat that question?
Dr Lin. Did you find any synergistic effects if you inhibited
both SMO and Gli simultaneously?
Dr Nguyen. Yes. A report was published by Beachy’s group
from Stanford studying combining ITRA and ATO (Cancer Cell.
2013;23:23-34). Yes, that would be something that we can do, is
to combine, targeting different levels of the pathway. As you
know, when you treat cells with GDC, SMO mutants emerge
that are resistant to the drug. We must find a method to overcome
that. One way of doing it would be to target downstream of SMO,
such as at the Gli level.
Dr Lin. Congratulations on your work.ery c January 2014
